SCHEMBL3083287

SCHEMBL3083287

N#Cc1cc(S(=O)(=O)Nc2cc(Cl)ccc2C(=O)c2ccccc2)ccc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 5/20 0.55
LMNA P02545 2/20 0.53
HTT P42858 2/20 0.53
HSP90AA1 P07900 1/20 0.48
HSP90AB1 P08238 1/20 0.48
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
CCR2 P41597 4/20 0.45
GPR27 Q9NS67 1/20 0.45
PGR P06401 1/20 0.45
BDKRB1 P46663 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
CCR4 P51679 1/20 0.45
CCR5 P51681 1/20 0.45
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3078432 0.87 LMNA (0.60) ACLYLMNAHTTTP53MAPT
SCHEMBL13180354 0.84 LMNA (0.56) ACLYLMNAHTTTP53MAPT
SCHEMBL3090152 0.83 LMNA (0.70) LMNAHTTHSP90AA1HSP90AB1TP53
SCHEMBL13146456 0.78 CCR2 (0.62) LMNAHTTCCR2
SCHEMBL13146558 0.77 LMNA (0.71) ACLYLMNAHTTTP53MAPT
SCHEMBL3089394 0.77 ACLY (0.62) ACLYLMNAHTTKMT2ACCR2
SCHEMBL29335 0.76 LMNA (0.73) LMNAHTTTP53MAPTKMT2A
SCHEMBL12221304 0.76 CCR9 (0.66) LMNAHTTCCR2BDKRB1CCR9
SCHEMBL28518 0.75 LMNA (0.80) LMNAHTTTP53MAPTKMT2A
SCHEMBL22234394 0.75 ACLY (0.66) ACLYHSP90AA1HSP90AB1SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed
WO-2008008374-A2 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. (US) 2008-01-17 WO disclosed
WO-2008008374-A2 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CCR2, CCR9, CCR1 ACLY 3799/4885LMNA 4007/4885HTT 3097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.